ID   VP13C_HUMAN             Reviewed;        3753 AA.
AC   Q709C8; Q6ISR4; Q702P2; Q702P3; Q709C9; Q9NXN8; Q9P2C6;
DT   28-NOV-2006, integrated into UniProtKB/Swiss-Prot.
DT   05-JUL-2004, sequence version 1.
DT   28-JUN-2023, entry version 146.
DE   RecName: Full=Intermembrane lipid transfer protein VPS13C {ECO:0000303|PubMed:30093493};
DE   AltName: Full=Vacuolar protein sorting-associated protein 13C {ECO:0000305};
GN   Name=VPS13C {ECO:0000312|EMBL:AAH69387.1};
GN   Synonyms=KIAA1421 {ECO:0000312|EMBL:BAA92659.1};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1] {ECO:0000305, ECO:0000312|EMBL:CAE75583.1}
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1; 2; 3 AND 4), AND TISSUE
RP   SPECIFICITY.
RC   TISSUE=Lymphoblast {ECO:0000269|PubMed:15498460};
RX   PubMed=15498460; DOI=10.1016/j.ygeno.2004.04.012;
RA   Velayos-Baeza A., Vettori A., Copley R.R., Dobson-Stone C., Monaco A.P.;
RT   "Analysis of the human VPS13 gene family.";
RL   Genomics 84:536-549(2004).
RN   [2] {ECO:0000305, ECO:0000312|EMBL:BAA92659.1}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1-1439 (ISOFORMS 1/2), AND
RP   VARIANT LYS-974.
RC   TISSUE=Brain {ECO:0000312|EMBL:BAA92659.1};
RX   PubMed=10718198; DOI=10.1093/dnares/7.1.65;
RA   Nagase T., Kikuno R., Ishikawa K., Hirosawa M., Ohara O.;
RT   "Prediction of the coding sequences of unidentified human genes. XVI. The
RT   complete sequences of 150 new cDNA clones from brain which code for large
RT   proteins in vitro.";
RL   DNA Res. 7:65-73(2000).
RN   [3] {ECO:0000305, ECO:0000312|EMBL:BAA90972.1}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 3305-3753 (ISOFORMS 1/3).
RC   TISSUE=Colon {ECO:0000312|EMBL:BAA90972.1};
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4] {ECO:0000305, ECO:0000312|EMBL:AAH69387.1}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 3305-3753 (ISOFORMS 1/3).
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [6]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-614; SER-619; THR-624 AND
RP   SER-737, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [7]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-3538, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C.,
RA   Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [8]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [9]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E.,
RA   Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-terminal
RT   acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-737; SER-842 AND SER-3641,
RP   AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-2473, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [12]
RP   METHYLATION [LARGE SCALE ANALYSIS] AT ARG-3526, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Colon carcinoma;
RX   PubMed=24129315; DOI=10.1074/mcp.o113.027870;
RA   Guo A., Gu H., Zhou J., Mulhern D., Wang Y., Lee K.A., Yang V., Aguiar M.,
RA   Kornhauser J., Jia X., Ren J., Beausoleil S.A., Silva J.C., Vemulapalli V.,
RA   Bedford M.T., Comb M.J.;
RT   "Immunoaffinity enrichment and mass spectrometry analysis of protein
RT   methylation.";
RL   Mol. Cell. Proteomics 13:372-387(2014).
RN   [13]
RP   FUNCTION, SUBCELLULAR LOCATION, INVOLVEMENT IN PARK23, AND VARIANT PARK23
RP   ARG-1389.
RX   PubMed=26942284; DOI=10.1016/j.ajhg.2016.01.014;
RG   French Parkinson's Disease Genetics Study (PDG);
RG   International Parkinson's Disease Genomics Consortium (IPDGC);
RG   International Parkinson's Disease Genomics Consortium IPDGC;
RA   Lesage S., Drouet V., Majounie E., Deramecourt V., Jacoupy M., Nicolas A.,
RA   Cormier-Dequaire F., Hassoun S.M., Pujol C., Ciura S., Erpapazoglou Z.,
RA   Usenko T., Maurage C.A., Sahbatou M., Liebau S., Ding J., Bilgic B.,
RA   Emre M., Erginel-Unaltuna N., Guven G., Tison F., Tranchant C.,
RA   Vidailhet M., Corvol J.C., Krack P., Leutenegger A.L., Nalls M.A.,
RA   Hernandez D.G., Heutink P., Gibbs J.R., Hardy J., Wood N.W., Gasser T.,
RA   Durr A., Deleuze J.F., Tazir M., Destee A., Lohmann E., Kabashi E.,
RA   Singleton A., Corti O., Brice A.;
RT   "Loss of mitochondrial morphology, transmembrane potential, and respiration
RT   function in autosomal-recessive parkinsonism causes mitochondrial
RT   dysfunction and increases PINK1/Parkin-dependent mitophagy.";
RL   Am. J. Hum. Genet. 98:500-513(2016).
RN   [14]
RP   VARIANT PHE-2872.
RX   PubMed=25787250; DOI=10.1073/pnas.1503696112;
RA   Cromer M.K., Choi M., Nelson-Williams C., Fonseca A.L., Kunstman J.W.,
RA   Korah R.M., Overton J.D., Mane S., Kenney B., Malchoff C.D., Stalberg P.,
RA   Akerstroem G., Westin G., Hellman P., Carling T., Bjoerklund P.,
RA   Lifton R.P.;
RT   "Neomorphic effects of recurrent somatic mutations in Yin Yang 1 in
RT   insulin-producing adenomas.";
RL   Proc. Natl. Acad. Sci. U.S.A. 112:4062-4067(2015).
RN   [15]
RP   SUBCELLULAR LOCATION, DOMAIN FFAT MOTIF, AND MUTAGENESIS OF
RP   878-TYR-PHE-879.
RX   PubMed=30093493; DOI=10.1083/jcb.201807019;
RA   Kumar N., Leonzino M., Hancock-Cerutti W., Horenkamp F.A., Li P.,
RA   Lees J.A., Wheeler H., Reinisch K.M., De Camilli P.;
RT   "VPS13A and VPS13C are lipid transport proteins differentially localized at
RT   ER contact sites.";
RL   J. Cell Biol. 217:3625-3639(2018).
CC   -!- FUNCTION: Mediates the transfer of lipids between membranes at
CC       organelle contact sites (By similarity). Necessary for proper
CC       mitochondrial function and maintenance of mitochondrial transmembrane
CC       potential (PubMed:26942284). Involved in the regulation of PINK1/PRKN-
CC       mediated mitophagy in response to mitochondrial depolarization
CC       (PubMed:26942284). {ECO:0000250|UniProtKB:Q07878,
CC       ECO:0000269|PubMed:26942284}.
CC   -!- SUBCELLULAR LOCATION: Mitochondrion outer membrane
CC       {ECO:0000269|PubMed:26942284}. Lipid droplet
CC       {ECO:0000269|PubMed:30093493}. Endoplasmic reticulum membrane
CC       {ECO:0000269|PubMed:30093493}. Lysosome membrane
CC       {ECO:0000269|PubMed:30093493}. Late endosome membrane
CC       {ECO:0000269|PubMed:30093493}. Note=May localize to endoplasmic
CC       reticulum-endolysosome contact sites. {ECO:0000269|PubMed:30093493}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=1 {ECO:0000269|PubMed:15498460}; Synonyms=2A
CC       {ECO:0000269|PubMed:15498460};
CC         IsoId=Q709C8-1; Sequence=Displayed;
CC       Name=2 {ECO:0000269|PubMed:15498460}; Synonyms=2B
CC       {ECO:0000269|PubMed:15498460};
CC         IsoId=Q709C8-2; Sequence=VSP_052244, VSP_052245;
CC       Name=3 {ECO:0000269|PubMed:15498460}; Synonyms=1A
CC       {ECO:0000269|PubMed:15498460};
CC         IsoId=Q709C8-3; Sequence=VSP_052243;
CC       Name=4 {ECO:0000269|PubMed:15498460}; Synonyms=1B
CC       {ECO:0000269|PubMed:15498460};
CC         IsoId=Q709C8-4; Sequence=VSP_052243, VSP_052244, VSP_052245;
CC   -!- TISSUE SPECIFICITY: Widely expressed. {ECO:0000269|PubMed:15498460}.
CC   -!- DOMAIN: The FFAT motif is required for localization to the endoplasmic
CC       reticulum. {ECO:0000269|PubMed:30093493}.
CC   -!- DISEASE: Parkinson disease 23, autosomal recessive, early onset
CC       (PARK23) [MIM:616840]: An autosomal recessive, early-onset form of
CC       Parkinson disease, a complex neurodegenerative disorder characterized
CC       by bradykinesia, resting tremor, muscular rigidity and postural
CC       instability, as well as by a clinically significant response to
CC       treatment with levodopa. The pathology involves the loss of
CC       dopaminergic neurons in the substantia nigra and the presence of Lewy
CC       bodies (intraneuronal accumulations of aggregated proteins), in
CC       surviving neurons in various areas of the brain.
CC       {ECO:0000269|PubMed:26942284}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the VPS13 family. {ECO:0000255}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAA90972.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC       Sequence=BAA92659.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AJ608770; CAE75582.1; -; mRNA.
DR   EMBL; AJ608771; CAE75583.1; -; mRNA.
DR   EMBL; AJ626860; CAF25187.1; -; mRNA.
DR   EMBL; AJ626861; CAF25188.1; -; mRNA.
DR   EMBL; AB037842; BAA92659.1; ALT_INIT; mRNA.
DR   EMBL; AK000143; BAA90972.1; ALT_INIT; mRNA.
DR   EMBL; BC069387; AAH69387.1; -; mRNA.
DR   CCDS; CCDS10180.1; -. [Q709C8-3]
DR   CCDS; CCDS32257.1; -. [Q709C8-1]
DR   CCDS; CCDS45272.1; -. [Q709C8-2]
DR   CCDS; CCDS58367.1; -. [Q709C8-4]
DR   RefSeq; NP_001018098.1; NM_001018088.2. [Q709C8-2]
DR   RefSeq; NP_060154.3; NM_017684.4. [Q709C8-3]
DR   RefSeq; NP_060550.2; NM_018080.3. [Q709C8-4]
DR   RefSeq; NP_065872.1; NM_020821.2. [Q709C8-1]
DR   SMR; Q709C8; -.
DR   BioGRID; 120186; 105.
DR   ELM; Q709C8; -.
DR   IntAct; Q709C8; 23.
DR   MINT; Q709C8; -.
DR   STRING; 9606.ENSP00000261517; -.
DR   CarbonylDB; Q709C8; -.
DR   GlyGen; Q709C8; 1 site, 1 O-linked glycan (1 site).
DR   iPTMnet; Q709C8; -.
DR   MetOSite; Q709C8; -.
DR   PhosphoSitePlus; Q709C8; -.
DR   BioMuta; VPS13C; -.
DR   DMDM; 74712594; -.
DR   EPD; Q709C8; -.
DR   jPOST; Q709C8; -.
DR   MassIVE; Q709C8; -.
DR   MaxQB; Q709C8; -.
DR   PaxDb; Q709C8; -.
DR   PeptideAtlas; Q709C8; -.
DR   ProteomicsDB; 68512; -. [Q709C8-1]
DR   ProteomicsDB; 68513; -. [Q709C8-2]
DR   ProteomicsDB; 68514; -. [Q709C8-3]
DR   ProteomicsDB; 68515; -. [Q709C8-4]
DR   Antibodypedia; 50681; 13 antibodies from 8 providers.
DR   DNASU; 54832; -.
DR   Ensembl; ENST00000249837.7; ENSP00000249837.3; ENSG00000129003.19. [Q709C8-3]
DR   Ensembl; ENST00000395898.3; ENSP00000379235.3; ENSG00000129003.19. [Q709C8-4]
DR   Ensembl; ENST00000644861.2; ENSP00000493560.2; ENSG00000129003.19. [Q709C8-1]
DR   Ensembl; ENST00000645819.1; ENSP00000496179.1; ENSG00000129003.19. [Q709C8-2]
DR   GeneID; 54832; -.
DR   KEGG; hsa:54832; -.
DR   MANE-Select; ENST00000644861.2; ENSP00000493560.2; NM_020821.3; NP_065872.1.
DR   UCSC; uc002agz.4; human. [Q709C8-1]
DR   AGR; HGNC:23594; -.
DR   CTD; 54832; -.
DR   DisGeNET; 54832; -.
DR   GeneCards; VPS13C; -.
DR   HGNC; HGNC:23594; VPS13C.
DR   HPA; ENSG00000129003; Low tissue specificity.
DR   MalaCards; VPS13C; -.
DR   MIM; 608879; gene.
DR   MIM; 616840; phenotype.
DR   neXtProt; NX_Q709C8; -.
DR   OpenTargets; ENSG00000129003; -.
DR   Orphanet; 2828; Young-onset Parkinson disease.
DR   PharmGKB; PA134990089; -.
DR   VEuPathDB; HostDB:ENSG00000129003; -.
DR   eggNOG; KOG1809; Eukaryota.
DR   GeneTree; ENSGT00950000183083; -.
DR   HOGENOM; CLU_000135_1_1_1; -.
DR   InParanoid; Q709C8; -.
DR   OMA; WQLGFHM; -.
DR   OrthoDB; 199953at2759; -.
DR   PhylomeDB; Q709C8; -.
DR   TreeFam; TF300316; -.
DR   PathwayCommons; Q709C8; -.
DR   SignaLink; Q709C8; -.
DR   BioGRID-ORCS; 54832; 8 hits in 1163 CRISPR screens.
DR   ChiTaRS; VPS13C; human.
DR   GenomeRNAi; 54832; -.
DR   Pharos; Q709C8; Tbio.
DR   PRO; PR:Q709C8; -.
DR   Proteomes; UP000005640; Chromosome 15.
DR   RNAct; Q709C8; protein.
DR   Bgee; ENSG00000129003; Expressed in calcaneal tendon and 204 other tissues.
DR   ExpressionAtlas; Q709C8; baseline and differential.
DR   Genevisible; Q709C8; HS.
DR   GO; GO:0005737; C:cytoplasm; TAS:ParkinsonsUK-UCL.
DR   GO; GO:0005829; C:cytosol; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0032127; C:dense core granule membrane; IEA:Ensembl.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; IDA:UniProtKB.
DR   GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB.
DR   GO; GO:0019898; C:extrinsic component of membrane; IBA:GO_Central.
DR   GO; GO:0005770; C:late endosome; IDA:UniProtKB.
DR   GO; GO:0031902; C:late endosome membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005811; C:lipid droplet; IDA:UniProtKB.
DR   GO; GO:0005765; C:lysosomal membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005764; C:lysosome; IDA:UniProtKB.
DR   GO; GO:0005741; C:mitochondrial outer membrane; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0006895; P:Golgi to endosome transport; TAS:ParkinsonsUK-UCL.
DR   GO; GO:0006869; P:lipid transport; IEA:UniProtKB-KW.
DR   GO; GO:0007005; P:mitochondrion organization; IMP:ParkinsonsUK-UCL.
DR   GO; GO:1905090; P:negative regulation of parkin-mediated stimulation of mitophagy in response to mitochondrial depolarization; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0045053; P:protein retention in Golgi apparatus; IBA:GO_Central.
DR   GO; GO:0006623; P:protein targeting to vacuole; IBA:GO_Central.
DR   GO; GO:0032868; P:response to insulin; IEA:Ensembl.
DR   InterPro; IPR015412; Atg2/VPS13_C.
DR   InterPro; IPR026847; VPS13.
DR   InterPro; IPR026854; VPS13-like_N.
DR   InterPro; IPR031645; VPS13_DH-like.
DR   InterPro; IPR031646; VPS13_extend_chorein.
DR   InterPro; IPR031642; VPS13_mid_RBG.
DR   InterPro; IPR009543; VPS13_VAB.
DR   PANTHER; PTHR16166:SF125; VACUOLAR PROTEIN SORTING-ASSOCIATED PROTEIN 13C; 1.
DR   PANTHER; PTHR16166; VACUOLAR PROTEIN SORTING-ASSOCIATED PROTEIN VPS13; 1.
DR   Pfam; PF09333; ATG_C; 1.
DR   Pfam; PF12624; Chorein_N; 1.
DR   Pfam; PF06650; SHR-BD; 1.
DR   Pfam; PF16908; VPS13; 1.
DR   Pfam; PF16909; VPS13_C; 1.
DR   Pfam; PF16910; VPS13_mid_rpt; 3.
PE   1: Evidence at protein level;
KW   Acetylation; Alternative splicing; Disease variant; Endoplasmic reticulum;
KW   Endosome; Lipid droplet; Lipid transport; Lysosome; Membrane; Methylation;
KW   Mitochondrion; Mitochondrion outer membrane; Neurodegeneration;
KW   Parkinson disease; Parkinsonism; Phosphoprotein; Reference proteome;
KW   Transport.
FT   CHAIN           1..3753
FT                   /note="Intermembrane lipid transfer protein VPS13C"
FT                   /id="PRO_0000262949"
FT   DOMAIN          3..116
FT                   /note="Chorein N-terminal"
FT                   /evidence="ECO:0000255"
FT   DOMAIN          2766..3016
FT                   /note="SHR-BD"
FT                   /evidence="ECO:0000255"
FT   REGION          150..176
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          2415..3309
FT                   /note="Required for late endosome/lysosome localization"
FT                   /evidence="ECO:0000269|PubMed:30093493"
FT   REGION          3310..3753
FT                   /note="Required for lipid droplet localization"
FT                   /evidence="ECO:0000269|PubMed:30093493"
FT   MOTIF           877..883
FT                   /note="FFAT"
FT                   /evidence="ECO:0000305"
FT   COMPBIAS        150..164
FT                   /note="Basic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOD_RES         132
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8BX70"
FT   MOD_RES         614
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:19690332"
FT   MOD_RES         619
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19690332"
FT   MOD_RES         624
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:19690332"
FT   MOD_RES         737
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19690332,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         842
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         872
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8BX70"
FT   MOD_RES         874
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8BX70"
FT   MOD_RES         1979
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8BX70"
FT   MOD_RES         2473
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   MOD_RES         3519
FT                   /note="Omega-N-methylarginine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8BX70"
FT   MOD_RES         3526
FT                   /note="Omega-N-methylarginine"
FT                   /evidence="ECO:0007744|PubMed:24129315"
FT   MOD_RES         3538
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   MOD_RES         3641
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   VAR_SEQ         129..171
FT                   /note="Missing (in isoform 3 and isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:15498460"
FT                   /id="VSP_052243"
FT   VAR_SEQ         3622..3627
FT                   /note="NHIKKL -> QELEIQE (in isoform 2 and isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:15498460"
FT                   /id="VSP_052244"
FT   VAR_SEQ         3628..3753
FT                   /note="Missing (in isoform 2 and isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:15498460"
FT                   /id="VSP_052245"
FT   VARIANT         153
FT                   /note="R -> H (in dbSNP:rs12595158)"
FT                   /id="VAR_029548"
FT   VARIANT         974
FT                   /note="R -> K (in dbSNP:rs3784634)"
FT                   /evidence="ECO:0000269|PubMed:10718198"
FT                   /id="VAR_029549"
FT   VARIANT         1132
FT                   /note="I -> V (in dbSNP:rs3784635)"
FT                   /id="VAR_029550"
FT   VARIANT         1302
FT                   /note="Y -> C (in dbSNP:rs2303405)"
FT                   /id="VAR_029551"
FT   VARIANT         1389
FT                   /note="G -> R (in PARK23; dbSNP:rs369100678)"
FT                   /evidence="ECO:0000269|PubMed:26942284"
FT                   /id="VAR_076363"
FT   VARIANT         1485
FT                   /note="T -> A (in dbSNP:rs8026956)"
FT                   /id="VAR_029552"
FT   VARIANT         1495
FT                   /note="I -> V (in dbSNP:rs11629598)"
FT                   /id="VAR_029553"
FT   VARIANT         1592
FT                   /note="S -> Y (in dbSNP:rs11629838)"
FT                   /id="VAR_029554"
FT   VARIANT         2322
FT                   /note="V -> M (in dbSNP:rs12907567)"
FT                   /id="VAR_029555"
FT   VARIANT         2808
FT                   /note="K -> R (in dbSNP:rs34060567)"
FT                   /id="VAR_053808"
FT   VARIANT         2872
FT                   /note="C -> F"
FT                   /evidence="ECO:0000269|PubMed:25787250"
FT                   /id="VAR_074191"
FT   VARIANT         2913
FT                   /note="S -> N (in dbSNP:rs10851704)"
FT                   /id="VAR_029556"
FT   MUTAGEN         878..879
FT                   /note="YF->SL: Abnormal localization to the cytosol."
FT                   /evidence="ECO:0000269|PubMed:30093493"
SQ   SEQUENCE   3753 AA;  422390 MW;  8B51A6778A89F639 CRC64;
     MVLESVVADL LNRFLGDYVE NLNKSQLKLG IWGGNVALDN LQIKENALSE LDVPFKVKAG
     QIDKLTLKIP WKNLYGEAVV ATLEGLYLLV VPGASIKYDA VKEEKSLQDV KQKELSRIEE
     ALQKAAEKGT HSGEFIYGLE NFVYKDIKPG RKRKKHKKHF KKPFKGLDRS KDKPKEAKKD
     TFVEKLATQV IKNVQVKITD IHIKYEDDVT DPKRPLSFGV TLGELSLLTA NEHWTPCILN
     EADKIIYKLI RLDSLSAYWN VNCSMSYQRS REQILDQLKN EILTSGNIPP NYQYIFQPIS
     ASAKLYMNPY AESELKTPKL DCNIEIQNIA IELTKPQYLS MIDLLESVDY MVRNAPYRKY
     KPYLPLHTNG RRWWKYAIDS VLEVHIRRYT QMWSWSNIKK HRQLLKSYKI AYKNKLTQSK
     VSEEIQKEIQ DLEKTLDVFN IILARQQAQV EVIRSGQKLR KKSADTGEKR GGWFSGLWGK
     KESKKKDEES LIPETIDDLM TPEEKDKLFT AIGYSESTHN LTLPKQYVAH IMTLKLVSTS
     VTIRENKNIP EILKIQIIGL GTQVSQRPGA QALKVEAKLE HWYITGLRQQ DIVPSLVASI
     GDTTSSLLKI KFETNPEDSP ADQTLIVQSQ PVEVIYDAKT VNAVVEFFQS NKGLDLEQIT
     SATLMKLEEI KERTATGLTH IIETRKVLDL RINLKPSYLV VPQTGFHHEK SDLLILDFGT
     FQLNSKDQGL QKTTNSSLEE IMDKAYDKFD VEIKNVQLLF ARAEETWKKC RFQHPSTMHI
     LQPMDIHVEL AKAMVEKDIR MARFKVSGGL PLMHVRISDQ KMKDVLYLMN SIPLPQKSSA
     QSPERQVSSI PIISGGTKGL LGTSLLLDTV ESESDDEYFD AEDGEPQTCK SMKGSELKKA
     AEVPNEELIN LLLKFEIKEV ILEFTKQQKE EDTILVFNVT QLGTEATMRT FDLTVVSYLK
     KISLDYHEIE GSKRKPLHLI SSSDKPGLDL LKVEYIKADK NGPSFQTAFG KTEQTVKVAF
     SSLNLLLQTQ ALVASINYLT TIIPSDDQSI SVAKEVQIST EKQQKNSTLP KAIVSSRDSD
     IIDFRLFAKL NAFCVIVCNE KNNIAEIKIQ GLDSSLSLQS RKQSLFARLE NIIVTDVDPK
     TVHKKAVSIM GNEVFRFNLD LYPDATEGDL YTDMSKVDGV LSLNVGCIQI VYLHKFLMSL
     LNFLNNFQTA KESLSAATAQ AAERAATSVK DLAQRSFRVS INIDLKAPVI VIPQSSISTN
     AVVVDLGLIR VHNQFSLVSD EDYLNPPVID RMDVQLTKLT LYRTVIQPGI YHPDIQLLHP
     INLEFLVNRN LAASWYHKVP VVEIKGHLDS MNVSLNQEDL NLLFRILTEN LCEGTEDLDK
     VKPRVQETGE IKEPLEISIS QDVHDSKNTL TTGVEEIRSV DIINMLLNFE IKEVVVTLMK
     KSEKKGRPLH ELNVLQLGME AKVKTYDMTA KAYLKKISMQ CFDFTDSKGE PLHIINSSNV
     TDEPLLKMLL TKADSDGPEF KTIHDSTKQR LKVSFASLDL VLHLEALLSF MDFLSSAAPF
     SEPSSSEKES ELKPLVGESR SIAVKAVSSN ISQKDVFDLK ITAELNAFNV FVCDQKCNIA
     DIKIHGMDAS ISVKPKQTDV FARLKDIIVM NVDLQSIHKK AVSILGDEVF RFQLTLYPDA
     TEGEAYADMS KVDGKLSFKV GCIQIVYVHK FFMSLLNFLN NFQTAKEALS TATVQAAERA
     ASSMKDLAQK SFRLLMDINL KAPVIIIPQS SVSPNAVIAD LGLIRVENKF SLVPMEHYSL
     PPVIDKMNIE LTQLKLSRTI LQASLPQNDI EILKPVNMLL SIQRNLAAAW YVQIPGMEIK
     GKLKPMQVAL SEDDLTVLMK ILLENLGEAS SQPSPTQSVQ ETVRVRKVDV SSVPDHLKEQ
     EDWTDSKLSM NQIVSLQFDF HFESLSIILY NNDINQESGV AFHNDSFQLG ELRLHLMASS
     GKMFKDGSMN VSVKLKTCTL DDLREGIERA TSRMIDRKND QDNNSSMIDI SYKQDKNGSQ
     IDAVLDKLYV CASVEFLMTV ADFFIKAVPQ SPENVAKETQ ILPRQTATGK VKIEKDDSVR
     PNMTLKAMIT DPEVVFVASL TKADAPALTA SFQCNLSLST SKLEQMMEAS VRDLKVLACP
     FLREKRGKNI TTVLQPCSLF MEKCTWASGK QNINIMVKEF IIKISPIILN TVLTIMAALS
     PKTKEDGSKD TSKEMENLWG IKSINDYNTW FLGVDTATEI TESFKGIEHS LIEENCGVVV
     ESIQVTLECG LGHRTVPLLL AESKFSGNIK NWTSLMAAVA DVTLQVHYYN EIHAVWEPLI
     ERVEGKRQWN LRLDVKKNPV QDKSLLPGDD FIPEPQMAIH ISSGNTMNIT ISKSCLNVFN
     NLAKGFSEGT ASTFDYSLKD RAPFTVKNAV GVPIKVKPNC NLRVMGFPEK SDIFDVDAGQ
     NLELEYASMV PSSQGNLSIL SRQESSFFTL TIVPHGYTEV ANIPVARPGR RLYNVRNPNA
     SHSDSVLVQI DATEGNKVIT LRSPLQIKNH FSIAFIIYKF VKNVKLLERI GIARPEEEFH
     VPLDSYRCQL FIQPAGILEH QYKESTTYIS WKEELHRSRE VRCMLQCPSV EVSFLPLIVN
     TVALPDELSY ICTHGEDWDV AYIIHLYPSL TLRNLLPYSL RYLLEGTAET HELAEGSTAD
     VLHSRISGEI MELVLVKYQG KNWNGHFRIR DTLPEFFPVC FSSDSTEVTT VDLSVHVRRI
     GSRMVLSVFS PYWLINKTTR VLQYRSEDIH VKHPADFRDI ILFSFKKKNI FTKNKVQLKI
     STSAWSSSFS LDTVGSYGCV KCPANNMEYL VGVSIKMSSF NLSRIVTLTP FCTIANKSSL
     ELEVGEIASD GSMPTNKWNY IASSECLPFW PESLSGKLCV RVVGCEGSSK PFFYNRQDNG
     TLLSLEDLNG GILVDVNTAE HSTVITFSDY HEGSAPALIM NHTPWDILTY KQSGSPEEMV
     LLPRQARLFA WADPTGTRKL TWTYAANVGE HDLLKDGCGQ FPYDANIQIH WVSFLDGRQR
     VLLFTDDVAL VSKALQAEEM EQADYEITLS LHSLGLSLVN NESKQEVSYI GITSSGVVWE
     VKPKQKWKPF SQKQIILLEQ SYQKHQISRD HGWIKLDNNF EVNFDKDPME MRLPIRSPIK
     RDFLSGIQIE FKQSSHQRSL RARLYWLQVD NQLPGAMFPV VFHPVAPPKS IALDSEPKPF
     IDVSVITRFN EYSKVLQFKY FMVLIQEMAL KIDQGFLGAI IALFTPTTDP EAERRRTKLI
     QQDIDALNAE LMETSMTDMS ILSFFEHFHI SPVKLHLSLS LGSGGEESDK EKQEMFAVHS
     VNLLLKSIGA TLTDVDDLIF KLAYYEIRYQ FYKRDQLIWS VVRHYSEQFL KQMYVLVLGL
     DVLGNPFGLI RGLSEGVEAL FYEPFQGAVQ GPEEFAEGLV IGVRSLFGHT VGGAAGVVSR
     ITGSVGKGLA AITMDKEYQQ KRREELSRQP RDFGDSLARG GKGFLRGVVG GVTGIITKPV
     EGAKKEGAAG FFKGIGKGLV GAVARPTGGI VDMASSTFQG IQRAAESTEE VSSLRPPRLI
     HEDGIIRPYD RQESEGSDLL ENHIKKLEGE TYRYHCAIPG SKKTILMVTN RRVLCIKEVE
     ILGLMCVDWQ CPFEDFVFPP SVSENVLKIS VKEQGLFHKK DSANQGCVRK VYLKDTATAE
     RACNAIEDAQ STRQQQKLMK QSSVRLLRPQ LPS
//
